Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| ciliated cell | 6 studies | 28% ± 13% | |
| epithelial cell | 4 studies | 41% ± 18% | |
| non-classical monocyte | 3 studies | 25% ± 5% | |
| fibroblast | 3 studies | 20% ± 2% | |
| dendritic cell | 3 studies | 20% ± 4% |
Insufficient scRNA-seq data for expression of ING2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| breast | 100% | 413.27 | 459 / 459 | 100% | 18.06 | 1115 / 1118 |
| pancreas | 100% | 376.84 | 327 / 328 | 100% | 13.64 | 178 / 178 |
| thymus | 100% | 460.35 | 653 / 653 | 100% | 20.52 | 603 / 605 |
| prostate | 100% | 425.79 | 245 / 245 | 100% | 13.11 | 500 / 502 |
| intestine | 100% | 438.88 | 963 / 966 | 100% | 10.67 | 525 / 527 |
| ovary | 100% | 1771.68 | 180 / 180 | 99% | 10.38 | 427 / 430 |
| stomach | 100% | 427.96 | 359 / 359 | 99% | 9.87 | 284 / 286 |
| bladder | 100% | 554.52 | 21 / 21 | 99% | 12.16 | 499 / 504 |
| brain | 99% | 433.58 | 2614 / 2642 | 100% | 14.94 | 704 / 705 |
| uterus | 99% | 299.95 | 169 / 170 | 99% | 19.88 | 456 / 459 |
| lung | 99% | 428.26 | 571 / 578 | 100% | 13.48 | 1153 / 1155 |
| esophagus | 100% | 906.05 | 1445 / 1445 | 98% | 11.84 | 180 / 183 |
| kidney | 100% | 473.91 | 89 / 89 | 98% | 11.14 | 884 / 901 |
| skin | 100% | 590.79 | 1809 / 1809 | 97% | 10.57 | 456 / 472 |
| adrenal gland | 100% | 1954.87 | 258 / 258 | 97% | 24.84 | 222 / 230 |
| liver | 95% | 244.13 | 215 / 226 | 92% | 6.46 | 373 / 406 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 12.80 | 29 / 29 |
| spleen | 100% | 425.80 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 20.02 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 6.67 | 1 / 1 |
| adipose | 100% | 427.74 | 1202 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 445.50 | 1331 / 1335 | 0% | 0 | 0 / 0 |
| muscle | 98% | 736.10 | 789 / 803 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 90% | 6.83 | 72 / 80 |
| peripheral blood | 90% | 320.95 | 836 / 929 | 0% | 0 | 0 / 0 |
| heart | 86% | 209.79 | 737 / 861 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0030511 | Biological process | positive regulation of transforming growth factor beta receptor signaling pathway |
| GO_0045814 | Biological process | negative regulation of gene expression, epigenetic |
| GO_1902455 | Biological process | negative regulation of stem cell population maintenance |
| GO_0007283 | Biological process | spermatogenesis |
| GO_2000772 | Biological process | regulation of cellular senescence |
| GO_0030512 | Biological process | negative regulation of transforming growth factor beta receptor signaling pathway |
| GO_0007165 | Biological process | signal transduction |
| GO_0006974 | Biological process | DNA damage response |
| GO_0072520 | Biological process | seminiferous tubule development |
| GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
| GO_0007141 | Biological process | male meiosis I |
| GO_1902459 | Biological process | positive regulation of stem cell population maintenance |
| GO_0030317 | Biological process | flagellated sperm motility |
| GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
| GO_0006355 | Biological process | regulation of DNA-templated transcription |
| GO_0048133 | Biological process | male germ-line stem cell asymmetric division |
| GO_1902166 | Biological process | negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator |
| GO_0030336 | Biological process | negative regulation of cell migration |
| GO_0007286 | Biological process | spermatid development |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0016602 | Cellular component | CCAAT-binding factor complex |
| GO_0070822 | Cellular component | Sin3-type complex |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0005634 | Cellular component | nucleus |
| GO_0035033 | Molecular function | histone deacetylase regulator activity |
| GO_0003677 | Molecular function | DNA binding |
| GO_0035064 | Molecular function | methylated histone binding |
| GO_0003682 | Molecular function | chromatin binding |
| GO_0044877 | Molecular function | protein-containing complex binding |
| GO_0035091 | Molecular function | phosphatidylinositol binding |
| GO_0140566 | Molecular function | histone reader activity |
| GO_0046872 | Molecular function | metal ion binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | ING2 |
| Protein name | Inhibitor of growth protein Inhibitor of growth protein 2 (Inhibitor of growth 1-like protein) (ING1Lp) (p32) (p33ING2) Inhibitor of growth family member 2 |
| Synonyms | ING1L |
| Description | FUNCTION: Seems to be involved in p53/TP53 activation and p53/TP53-dependent apoptotic pathways, probably by enhancing acetylation of p53/TP53. Component of a mSin3A-like corepressor complex, which is probably involved in deacetylation of nucleosomal histones. ING2 activity seems to be modulated by binding to phosphoinositides (PtdInsPs). . FUNCTION: Component of an histone acetyltransferase complex. . |
| Accessions | ENST00000412117.1 Q9H160 Q5GRH6 ENST00000302327.4 [Q9H160-1] C9J4X5 |
